Literature DB >> 23319408

An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials.

Yufen Huang1, Wan-Jung Chang, Chin-Fu Hsiao.   

Abstract

To accelerate the drug development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries/regions around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. In this paper, we focus on a specific region and establish a statistical criterion to assess the consistency between the specific region and overall results in an MRCT. More specifically, we treat each region in an MRCT as an independent clinical trial, and each perhaps has different treatment effect. We then construct the empirical prior information for the treatment effect for the specific region on the basis of all of the observed data from other regions. We will conclude similarity between the specific region and all regions if the posterior probability of deriving a positive treatment effect in the specific region is large, say 80%. Numerical examples illustrate applications of the proposed approach in different scenarios.
Copyright © 2013 John Wiley & Sons, Ltd.

Mesh:

Year:  2013        PMID: 23319408     DOI: 10.1002/pst.1553

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  1 in total

1.  Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints.

Authors:  Wong-Shian Huang; Hui-Nien Hung; Toshimitsu Hamasaki; Chin-Fu Hsiao
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.